Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease.

Objectives/hypothesis: To evaluate the efficacy and safety of bevacizumab administered at a concentration of 50 mg as an intranasal spray in the treatment of epistaxis in patients suffering from Rendu-Osler disease.

Study Design: Prospective.

Methods: A preliminary, prospective, review board-approved study was conducted on six patients with Rendu-Osler disease who received 10 treatment courses of 50 mg bevacizumab.

Hybrid titanium/biodegradable polymer implants with an hierarchical pore structure as a means to control selective cell movement.

Unlabelled: In order to improve implant success rate, it is important to enhance their responsiveness to the prevailing conditions following implantation. Uncontrolled movement of inflammatory cells and fibroblasts is one of these in vivo problems and the porosity properties of the implant have a strong effect on these. Here, we describe a hybrid system composed of a macroporous titanium structure filled with a microporous biodegradable polymer.